RCS - Redx Pharma plc - Presentation of RXC007 Preclinical Efficacy Data

Redx PharmaAnnouncement

11/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230511:nRSK0150Za&default-theme=true

RNS Number : 0150Z  Redx Pharma plc  11 May 2023

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx Presents Preclinical Efficacy Data for RXC007 Showing Significant Results
in Cancer-Associated Fibrosis Models

Alderley Park, UK, 11 May 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, targeted therapeutics for the treatment of cancer and fibrotic
disease announces additional preclinical data for its lead fibrosis asset,
RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme, as
presented yesterday at the Resistant Tumour Microenvironment, Keystone
Symposia, in Vancouver, BC.  The data presented were from preclinical models
of pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer
(TNBC), in combination with chemotherapy and immunotherapy, as current
standard of care.

RXC007, in combination with gemcitabine/Abraxane® i  (#_edn1) in metastatic
and high-extra cellular matrix (ECM) patient-derived PDAC models, was shown to
increase survival compared to single agent standard of care alone.  The
combination of RXC007 with standard of care provided a significant increase in
median survival days from date of treatment in a dose dependent manner.
 These new data on RXC007 complement those also presented at the meeting by
collaboration partner the Garvan Institute of Medical Research ("the Garvan")
on REDX10616, a close analogue of RXC007, which were also presented at the
Extracellular Matrix Pharmacology congress last year.  These data show
REDX10616, in combination with FOLFIRINOX, re-sensitised a FOFIRINOX-resistant
patient derived xenograft (PDX) model to treatment and led to a striking
increase in survival in combination with the standard of care triplet
chemotherapy.

Taken together, these data provide a strong rationale for the potential of
ROCK2 inhibition in combination with standard of care as a potential treatment
for cancer-associated fibrosis. Redx plans to further investigate this
treatment setting with the Company's next-generation ROCK2 inhibitor, RXC007,
in the clinic.

Additionally, at the Keystone Symposia, further data were also presented from
Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models.  Using
a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771
model resulted in a statistically significant increase in survival when
compared to the control group, an effect not observed with either single agent
alone.

Caroline Phillips, Senior Vice President Biology, Redx Pharma commented:
"These data, presented in hard-to-treat preclinical models, highlights the
multiple opportunities for our lead asset RXC007.  RXC007 is a highly
selective, next-generation, ROCK2 inhibitor, currently in Phase 2a clinical
studies for IPF, which has shown significant potential in other disease areas
that we are excited to pursue in the future. Taken together with the data from
our DDR1/2 programme currently in lead optimization, this provides support for
new mechanisms to provide treatments for cancer-associated fibrosis which has
been associated with poor prognosis in several cancers."

 

 For further information, please contact:

 Redx Pharma Plc                                                      T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                          T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                       T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                           T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                       T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, targeted therapeutics
for the treatment of cancer and fibrotic disease and the emerging area of
cancer-associated fibrosis, aiming initially to progress them to clinical
proof of concept before evaluating options for further development and
potential value creation.  The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease being evaluated in a Phase 2a trial for idiopathic pulmonary fibrosis
(IPF) with topline data expected in Q1 2024. Redx's lead oncology product
candidate, the Porcupine inhibitor RXC004, being developed as a targeted
treatment for Wnt-ligand dependent cancers, is expected to report Phase 2 data
in combination with anti-PD-1 by end 2023.  Redx's third drug candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is progressing towards a CTA application in H2 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult
patients with mantle cell lymphoma previously treated with a covalent BTK
inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic
diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical
study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now
progressing through Phase 1 clinical studies, and an early stage oncology
research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

 

 

 

 

 

 

 i  (#_ednref1) ABRAXANE(®) is a registered trademark of Abraxis BioScience,
LLC, a Bristol-Myers Squibb Company.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFEFWSEDSEEI